PL3030232T3 - Gojenie ran poprzez autologiczną mobilizację komórek macierzystych - Google Patents

Gojenie ran poprzez autologiczną mobilizację komórek macierzystych

Info

Publication number
PL3030232T3
PL3030232T3 PL14791563.1T PL14791563T PL3030232T3 PL 3030232 T3 PL3030232 T3 PL 3030232T3 PL 14791563 T PL14791563 T PL 14791563T PL 3030232 T3 PL3030232 T3 PL 3030232T3
Authority
PL
Poland
Prior art keywords
stem cell
wound healing
autologous stem
cell mobilization
healing via
Prior art date
Application number
PL14791563.1T
Other languages
English (en)
Inventor
Zhaoli Sun
George Melville Williams
Qing Lin
Original Assignee
Medregen, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medregen, Llc filed Critical Medregen, Llc
Publication of PL3030232T3 publication Critical patent/PL3030232T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14791563.1T 2013-04-29 2014-04-29 Gojenie ran poprzez autologiczną mobilizację komórek macierzystych PL3030232T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361816827P 2013-04-29 2013-04-29
US201361907624P 2013-11-22 2013-11-22
PCT/US2014/035793 WO2014179266A2 (en) 2013-04-29 2014-04-29 Wound healing via autologous stem cell mobilization

Publications (1)

Publication Number Publication Date
PL3030232T3 true PL3030232T3 (pl) 2022-11-07

Family

ID=51844093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14791563.1T PL3030232T3 (pl) 2013-04-29 2014-04-29 Gojenie ran poprzez autologiczną mobilizację komórek macierzystych

Country Status (9)

Country Link
US (2) US10945993B2 (pl)
EP (2) EP4091609A1 (pl)
CN (2) CN113663077B (pl)
DK (1) DK3030232T3 (pl)
ES (1) ES2927803T3 (pl)
HU (1) HUE059749T2 (pl)
PL (1) PL3030232T3 (pl)
SI (1) SI3030232T1 (pl)
WO (1) WO2014179266A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
WO2017011750A1 (en) * 2015-07-16 2017-01-19 Medregen, Llc Pharmaceutical compositions useful for the treatment of tissue injury
CN107064137A (zh) * 2016-12-28 2017-08-18 钟叔平 一种无创的皮肤创面采样观察及分析方法
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL302773A (en) 2020-11-10 2023-07-01 Medregen Llc Formulations, methods, kits and dosage forms
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
JP2026525902A (ja) * 2023-07-10 2026-08-04 メドレジェン,リミティド ライアビリティ カンパニー 経路のダウンレギュレーションおよびアップレギュレーション方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5365948A (en) 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
WO2000067776A1 (en) 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1487795B1 (en) 2001-09-12 2010-11-03 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US20050058622A1 (en) 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
US7994214B2 (en) 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
EP1693065B1 (en) 2003-10-27 2012-12-26 Keio University Fibroblast-mobilizing agent containing g-csf and wound remedy
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CA2640087A1 (en) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
US20070292401A1 (en) 2006-06-20 2007-12-20 Harmon Alexander M Soft tissue repair and regeneration using stem cell products
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
EP2039348A1 (en) 2007-09-21 2009-03-25 Jürgen Schliefelbein Cosmetic preparation and method to obtain a somatic stem cell preparation
EP2237798A2 (en) 2007-12-12 2010-10-13 Imperial Innovations Limited Methods
WO2009094456A2 (en) 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2009114725A2 (en) 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
WO2010022017A2 (en) 2008-08-19 2010-02-25 Hartmut Geiger Method and composition for enhancing hematopoietic stem cell mobilization
EP2356128A1 (en) 2008-09-15 2011-08-17 Endotis Pharma Oligosaccharide compounds for use in mobilising stem cells
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US20120053119A1 (en) 2009-02-11 2012-03-01 Habener Joel F Therapeutic method for increasing pancreatic beta cell mass
US20100226894A1 (en) 2009-03-09 2010-09-09 Alex Wah Hin Yeung Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
LT2509619T (lt) 2009-12-11 2021-04-12 Medregen, Llc Gydymo būdai, naudojant kamieninių ląstelių mobilizatorius ir imunosupresijos agentus
EP2648727A4 (en) 2010-12-07 2014-05-07 Univ Johns Hopkins COMPOSITIONS AND METHOD FOR MOBILIZING STEM CELLS

Also Published As

Publication number Publication date
SI3030232T1 (sl) 2022-11-30
WO2014179266A9 (en) 2016-04-21
DK3030232T3 (da) 2022-10-10
EP3030232B1 (en) 2022-07-06
EP3030232A2 (en) 2016-06-15
WO2014179266A2 (en) 2014-11-06
US12048687B2 (en) 2024-07-30
US10945993B2 (en) 2021-03-16
EP4091609A1 (en) 2022-11-23
US20210251954A1 (en) 2021-08-19
ES2927803T3 (es) 2022-11-11
US20160106710A1 (en) 2016-04-21
CN113663077B (zh) 2024-03-15
EP3030232A4 (en) 2019-07-31
CN113663077A (zh) 2021-11-19
CN105658217B (zh) 2021-03-19
CN105658217A (zh) 2016-06-08
HUE059749T2 (hu) 2022-12-28

Similar Documents

Publication Publication Date Title
IL245573A0 (en) cell
GB201302468D0 (en) Stem cell product
GB2516340B (en) Wound dressings
GB201303814D0 (en) Battery structure
PL2966327T3 (pl) Ulepszona konstrukcja zaworów trójdrożnych
SI3030232T1 (sl) Celjenje ran s pomočjo mobilizacije avtolognih matičnih celic
ZA201508186B (en) Methods and compositions for wound healing
EP2980873A4 (en) CRYOSTAT
GB201310031D0 (en) Cell
SG11201601408PA (en) Stem cell modulation ii
GB201310730D0 (en) New structure
GB2514561B (en) Overhearing
TWM476247U (en) Dehumidifier structure
GB2518246B (en) Greenhouse
PL3021877T3 (pl) Opatrunek na ranę
GB2511577B (en) Carrying structure
TWM476256U (en) Two-part stick structure
GB201311829D0 (en) Tweezers
GB201311905D0 (en) Bandage
GB201303217D0 (en) Bridges Research Application - BRA
AU2013900590A0 (en) App Staff
TWM476584U (en) Wound dressings
TWM476735U (en) Umbrella structure
TWM476968U (en) Meteorology lamp
GB201317589D0 (en) Cell